Crinetics Pharmaceuticals stock is soaring. What’s the outlook for CRNX shares?

Vertex To Acquire Crinetics

Crinetics and Vertex have entered into a definitive agreement under which Vertex will acquire Crinetics for $85 per share in cash, representing a total equity value of approximately $10 billion.

“Nearly 18 years ago, we founded Crinetics with a clear goal of transforming the lives of patients living with endocrine-related diseases. Today marks a historic milestone as we embark on this next chapter with Vertex,” said Scott Struthers, founder and CEO of Crinetics Pharmaceuticals.

“This partnership is anchored by a mutual commitment to science and a shared vision for delivering innovative treatments to patient communities that have long been underserved.”